Endocrine therapy Clinical Trials
11 recruitingDrug
Phase 26Phase 33Phase 11
Showing 1–11 of 11 trials
Recruiting
Phase 1Phase 2
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
Brain MetastasesHR+ Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute31 enrolled2 locationsNCT04923542
Recruiting
Phase 3
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
Breast Carcinoma
Institut Curie300 enrolled13 locationsNCT06195709
Recruiting
Phase 2
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Metastatic Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerRecurrent Breast Cancer
Puma Biotechnology, Inc.150 enrolled53 locationsNCT06369285
Recruiting
Phase 2
Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer
Breast Cancer
Xijing Hospital27 enrolled2 locationsNCT06914440
Recruiting
Phase 2
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
HER2-positive Breast Cancer
GBG Forschungs GmbH170 enrolled29 locationsNCT05306041
Recruiting
Phase 3
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
Metastatic Breast CancerAdvanced Breast CancerQuality of Life+2 more
Region Örebro County495 enrolled12 locationsNCT06044623
Recruiting
Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer
Advanced Breast CancerESR1 Gene Mutation
SciClone Pharmaceuticals450 enrolled1 locationNCT06548919
Recruiting
Phase 2
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
Early Breast Cancer
The First Affiliated Hospital with Nanjing Medical University1,163 enrolled1 locationNCT06341894
Recruiting
Phase 2
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
HR+/HER2- Advanced Breast CancerTargeted Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences102 enrolled1 locationNCT05983107
Recruiting
Phase 3
Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
HR Positive/HER2 Low Expression Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University288 enrolled3 locationsNCT05904964
Recruiting
Application of Radiomics in Breast Cancer
Breast CancerRadiomicsUltrasound+2 more
Second Affiliated Hospital, School of Medicine, Zhejiang University2,000 enrolled1 locationNCT04483804